Deutsche comments on Sarepta after Prosensa misses with drisapersen

Deutsche's Robyn Karnauskas is out with commentary on what Prosensa (RNA -69.8%) and GlaxoSmithKline's (GSK +0.6%) drisapersen data means for Sarepta (SRPT +2.4%)

Long story short, it's a good news-bad news scenario.

The good news is that this is now a one-horse race and that horse's name is eteplirsen. If the DMD treatment gets approved, it's obviously better to be the only drug on the market than to have competition.

The bad news is that DEMAND-III "highlights it is difficult to design a clinical trial in this patient segment" and presents some uncertainty regarding "what the FDA requirements [will be] for [eteplirsen] clinical trials."

Also: Stifel is apparently out with a positive call for SRPT

More here

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs